Table 3.
Relative risk estimates for impairment on verbal and visual memory
| Measure | % Affected
|
Patients
|
All siblings (λ)
|
Concordant Siblings (λ')
|
|||||||
|---|---|---|---|---|---|---|---|---|---|---|---|
| Patients | Siblings | Controls | RR | p(χ2) | RR | p(χ2) | N | RR | p(χ 2) | ||
| LM1 | 1SD | 78.40% | 27.40% | 16.10% | 4.9 | <.0001 (142.8) | 1.7 | .01 (6.6) | 86 | 1.7 | .02 (5.4) |
| 2SD | 41.40% | 6.20% | 1.50% | 28.3 | <.0001 (93.3) | 4.2 | .01 (5.7) | 45 | 4.6 | .04 (4.3) | |
| LM2 | 1SD | 79.00% | 28.80% | 17.60% | 4.5 | <.0001 (138.3) | 1.6 | .01 (6.2) | 83 | 1.9 | .005 (7.8) |
| 2SD | 43.20% | 8.90% | 2.00% | 22.2 | <.0001 (98.1) | 4.6 | .003 (8.9) | 45 | 5.7 | .003 (8.9) | |
| LM3 | 1SD | 80.90% | 28.80% | 17.60% | 4.6 | <.0001 (146.2) | 1.6 | .01 (6.2) | 85 | 1.7 | .02 (5.1) |
| 2SD | 41.40% | 6.90% | 1.00% | 42.4 | b.0001 (96.7) | 7 | .003 (8.9) | 43 | 7.2 | .01 (6.5) | |
| %R LM2/1 | 1SD | 50.60% | 22.00% | 13.20% | 3.8 | <.0001 (60.8) | 1.7 | .03 (4.67) | 50 | 2 | .03 (5.0) |
| 2SD | 31.50% | 11.60% | 2.00% | 16.1 | <.0001 (61.9) | 6 | .0002 (14.2) | 28 | 7.3 | .0008 (11.3) | |
| %R LM3/2 | 1SD | 34.80% | 21.90% | 15.20% | 2.3 | <.0001 (18.9) | 1.4 | .11 (2.6) | 40 | 1.2 | .71 (.14) |
| 2SD | 24.10% | 6.90% | 4.00% | 6.1 | <.0001 (32.5) | 1.8 | .22 (1.5) | 30 | 1.9 | .49 (.48) | |
| VR1 | 1SD | 51.30% | 18.20% | 10.10% | 5.1 | <.0001 (54.5) | 1.8 | .06 (3.6) | 39 | 2.5 | .01 (6.1) |
| 2SD | 30.10% | 3.50% | 5.40% | 5.6 | <.0001 (28.1) | 1.2 | .76 (.09) | 27 | 2.7 | .08 (3) | |
| VR2 | 1SD | 61.60% | 15.40% | 13.20% | 4.7 | <.0001 (69.7) | 1.2 | .60 (.27) | 63 | 1.6 | .18 (1.8) |
| 2SD | 37.70% | 3.50% | 5.40% | 7 | <.0001 (41.7) | .6 | .44 (12) | 34 | 1.1 | .92 (.01) | |
| VR3 | 1SD | 62.70% | 11.60% | 11.60% | 5.4 | <.0001 (77.2) | 1.6 | .13 (2.3) | 62 | 1.9 | .05 (3.9) |
| 2SD | 36.10% | 5.60% | 5.40% | 6.7 | <b.0001 (38.5) | 1 | .95 (.00) | 33 | 1.1 | .89 (.02) | |
| %R VR2/1 | 1SD | 53.50% | 14.00% | 14.70% | 3.6 | <.0001 (46.3) | 1 | .87 (.03) | 64 | 1.2 | .66 (.20) |
| 2SD | 35.20% | 3.50% | 4.60% | 7.6 | <.0001 (39.4) | .8 | .63 (.23) | 32 | 1.3 | .71 (.14) | |
| %R VR3/2 | 1SD | 27.20% | 11.20% | 10.10% | 2.7 | .0003 (13.3) | 1.1 | .78 (.09) | 25 | 1.2 | .77 (.08) |
| 2SD | 17.70% | 7.00% | 4.70% | 3.8 | .0007 (11.6) | 1.5 | .41 (.67) | 13 | 3.3 | .11 (2.6) | |
λ
= relative risk for all siblings (N=146 (LM); 143 (VR)); λ′=relative risk for “concordant siblings” subgroup, i.e., siblings of patients with cognitive impairment for test (N indicates total concordant siblings for each measure). All χ2 tests compare distribution in siblings with that in controls (N=205 (LM); 519 (VR)). Criteria used to define “affected” status of subjects are one (1SD) and two (2SD) standard deviations below mean of control group. Bold numbers indicate significance of p≤.05.